PTAB upheld 23 claims of Seer Inc.'s U.S. Patent No. 11,435,360, including five challenged claims, validating the company's nanoparticle protein enrichment technology for the Proteograph platform.
Key takeaways
PTAB issued Final Written Decision on March 23, 2026, upholding claims 2, 3, 7, 23, 24 of the ‘360 patent.
23 claims total remain valid and enforceable, including 5 upheld and 18 unchallenged.
Petitioners PreOmics GmbH and Biognosys AG (Bruker subsidiaries) challenged claims 1-4, 6, 7, 17, 22-25; claims 1, 4, 6, 22, 25 found unpatentable.
‘360 Patent covers methods using engineered nano- and microparticles for protein coronas in proteomic analysis, exclusively licensed to Seer.
Upheld claims relate to protein detection depth, dynamic range, and particle aspects supporting Proteograph Product Suite.
Appeal notice must be filed by May 25, 2026 if pursued by either party.